Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

This Phase II, single arm study evaluates a PSA-response-adapted approach to salvage radiotherapy after radical prostatectomy for prostate cancer. All participants will receive hypo-fractionated stereotactic radiotherapy to the prostate fossa. At 5 weeks, biochemical response will be assessed. responders will proceed to observation, while non responders will receive sequential pelvic nodal radiotherapy and 4 months of androgen deprivation therapy (ADT). The study aims to determine whether this response base approach achieves non inferior 2 year freedom from progression compared with historical outcomes using routine pelvic nodal radiotherapy and ADT in all patients.

NCT Number	NCT07313241
Lead Sponsor	University of Texas Southwestern Medical Center
Conditions	Prostate Cancer
Enrollment	68 participants
Start Date	2025-11-14
Primary Completion	2030-11-14 (estimated)
Study Completion	2030-11-14 (estimated)
Updated on ClinicalTrials.gov	2026-06-30